Related topics: Industry Drivers
India’s Sun Pharmaceutical Industries is worried about the FDA warning letter received by a Canadian manufacturing facility owned by its acquisition target Taro Pharmaceutical.
Sun told India’s Business Standard that: “We are quite concerned about this development,” which saw the US Food and Drug Administration (FDA) criticise Taro’s plant in Brampton, Ontario that makes some of its leading brands like Dermovate, HydroVal, Ketoderm, Lyderm and Tiamol
Taro, which is currently appealing an Israeli court ruling in favour of Sun in the pair’s takeover tussle, said it will respond to the FDA’s criticism of the Brampton site in the next 30 days.
Copyright - Unless otherwise stated all contents of this web site are © 2000/2009 - Decision News Media SAS - All Rights Reserved - For permission to reproduce any contents of this web site, please email our Syndication department: Administration & Finance - Full details for the use of materials on this site can be found in the Terms & Conditions
Food & Beverage: Food & Beverage Development - Europe | Food & Beverage Development - North America | Food Marketing and Retailing | Food Processing & Packaging | Food Safety & Quality Control | Food and Beverage in Asia Pacific | Industrial Baking & Snacks | Beverage Technology & Markets | Confectionery & Biscuit Processing | Dairy Processing & Markets | Prepared Food and Meat Processing Nutrition: Supplements & Nutrition - Europe | Supplements & Nutrition - North America Pharmaceutical: Pharmaceutical Technology | Contract Research, Manufacturing & Clinical Trials Cosmetics: Cosmetics Formulation & Packaging - North America | Cosmetics Formulation & Packaging - Europe
© 2000/2009 - Decision News Media SAS - All right reserved.
